Integer Holdings Corp: directors' dealings · United States · SEC (Form 4)

About Integer Holdings Corp

Integer Holdings Corp. (NYSE: ITGR) is a U.S.-listed healthcare manufacturing company focused on medical device contract development and manufacturing. Based on the company’s investor materials, Integer is one of the largest medical device CDMOs in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. Its commercial brands include Greatbatch Medical® and Lake Region Medical®, reflecting a portfolio built around engineering-intensive, high-reliability medical technology solutions. ([investor.integer.net](https://investor.integer.net/overview/?utm_source=openai)) The company’s roots trace back to Greatbatch, Inc., which was renamed Integer Holdings Corporation in 2016. That change marked a broader repositioning around a more integrated identity and an emphasis on advanced engineering and manufacturing for medical device customers. Integer’s headquarters are in Plano, Texas, United States, and the company serves customers across a global footprint, while remaining firmly anchored in the U.S. capital markets through its listing on the NYSE. ([investor.integer.net](https://investor.integer.net/news-events/press-releases/news-details/2016/Greatbatch-Inc-Renamed-Integer-Holdings-Corporation/default.aspx?utm_source=openai)) Operationally, Integer’s value proposition is end-to-end: design support, development, manufacturing, quality systems, and scale production. The company’s core strength lies in helping original equipment manufacturers move complex medical technologies from concept to commercialization faster and with lower development risk. Its capabilities span implantable and precision components, device subassemblies, and products used in cardiac rhythm management and neuromodulation therapies. In a sector where regulatory compliance, precision, and supply reliability matter enormously, that integrated model is a key competitive advantage. ([investor.integer.net](https://investor.integer.net/overview/?utm_source=openai)) From a competitive standpoint, Integer is positioned as a scaled specialist rather than a broad diversified healthcare conglomerate. Its differentiation comes from deep technical know-how, long-term customer relationships, a broad and diversified product pipeline, and exposure to attractive end markets with structural growth drivers. Those factors can support recurring program wins and make the company strategically important to major medtech OEMs. ([investor.integer.net](https://investor.integer.net/news-events/press-releases/news-details/2026/Integer-Announces-Strategic-Review-to-Maximize-Stockholder-Value/default.aspx?utm_source=openai)) Recent developments are especially relevant for investors. On April 30, 2026, Integer announced a strategic review aimed at maximizing shareholder value, including the possibility of a sale, merger, or strategic business combination. The company also reported first-quarter 2026 results showing sales of $440 million and a cautious update to its outlook, while reiterating its longer-term target of returning to 200 basis points above-market organic sales growth in 2027. For investors tracking SEC Form 4 insider transactions, this combination of strategic review, operational execution, and capital structure evolution makes ITGR a closely watched name. ([investor.integer.net](https://investor.integer.net/news-events/press-releases/news-details/2026/Integer-Announces-Strategic-Review-to-Maximize-Stockholder-Value/default.aspx?utm_source=openai))